Ms Britt Heidemann
University Medical Center Utrecht, Utrecht (Netherlands (The))
Effect of evolocumab versus placebo added to standard lipid-lowering therapy on fasting and post fat load lipids and lipoproteins in familial dysbetalipoproteinemia
Event: ESC Congress 2022
Topic: Drug therapy
Session: Optimal risk factor therapy in high risk patients
Risk factors for the presence and development of Familial Dysbetalipoproteinemia in subjects from the general population with an APOE2E2 genotype
Event: ESC Congress 2020
Topic: Lipids
Session: Genetic Predisposition and Management of Dyslipidemia
Remnant cholesterol increases the risk for recurrent vascular events independent of ldl-cholesterol in patients with clinical manifest vascular disease.
Event: ESC Congress 2019
Topic: Lipids
Session: Lipids / Cardiovascular risk prediction / Life style
ESC 365 is supported by
